Conference on Q3 FY2025 (April 1, 2025 to December 31, 2025) Financial Results
Toru Kimura, President and CEO Sumitomo Pharma Co., Ltd.
January 30, 2026
Financial Results for Q3 FY2025
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 2
Financial Results for Q3 FY2025
Financial Results for Q3 FY2025 (Core Basis)Performance exceeds expectations Forecasts remain unchanged
Revenue increased primarily due to the growth of ORGOVYX® and GEMTESA® and sales milestone revenue from ORGOVYX®
SG&A expenses and R&D expenses decreased due to business structure improvements and realignment of the regenerative medicine and cell therapy business
Others (core basis)
FY2025: Gain on partial transfer of the Asian business +Â¥49.0B
Adjustment items:
FY2024: Business structure improvement expenses in Japan and North America
Billions of JPY
FY2025
Oct. 31 forecasts | % |
429.0 | 81.1 |
186.5 | 77.8 |
242.5 | 83.5 |
152.0 | 76.6 |
44.0 | 63.2 |
50.5 | |
97.0 | 112.8 |
1.0 | |
98.0 | 112.0 |
(12.0) | |
86.0 | 118.1 |
(6.0) | |
92.0 | 117.0 |
Q3YTD FY2024 Results | Q3YTD FY2025 Results | Change | |||
Value | FX impact | % | |||
Revenue | 293.2 | 347.7 | 54.6 | (7.6) | 18.6 |
Cost of sales | 113.5 | 145.1 | 31.6 | (2.1) | 27.9 |
Gross profit | 179.7 | 202.6 | 22.9 | (5.5) | 12.8 |
SG&A expenses | 124.4 | 116.4 | (8.0) | (2.2) | (6.4) |
R&D expenses | 35.4 | 27.8 | (7.5) | (0.5) | (21.3) |
Others (core basis) | 1.6 | 51.1 | 49.5 | ||
Core operating profit | 21.5 | 109.4 | 87.9 | (2.8) | 408.5 |
Adjustment items (negative number indicates net expense) | (8.3) | 0.3 | 8.6 | ||
Operating profit | 13.2 | 109.8 | 96.5 | 730.0 | |
Finance income/costs | 10.8 | (8.2) | (19.0) | ||
Profit before taxes | 24.0 | 101.5 | 77.5 | 322.6 | |
Income tax expenses | 2.8 | (6.1) | (8.9) | ||
Net profit attributable to owners of the parent | 21.2 | 107.7 | 86.5 | 407.5 | |
Average rates:
Q3 FY2024 Results : 1US$ = ¥152.64, 1RMB = ¥21.17 Q3 FY2025 Results : 1US$ = ¥148.71, 1RMB = ¥20.12 FY2025 forecasts : 1US$ = ¥145.00, 1RMB = ¥20.12
Period end rates:
As of the end of March 2025 : 1US$ = ¥149.53, 1RMB = ¥20.59 As of the end of Dec. 2025 : 1US$ = ¥156.53, 1RMB = ¥20.74
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 3
Financial Results for Q3 FY2025
Revenue of Major Products in North AmericaQ3YTD FY2024 Results | Q3YTD FY2025 Results | Change | Q3YTD FY2024 Results | Q3YTD FY2025 Results | Change | FY2025 | |||||
Value | FX impact | % | Oct. 31 forecasts | JPY-basis Progress % | |||||||
North America | Millions of USD | Billions of JPY | Millions of USD | Billions of JPY | |||||||
ORGOVYX® | 379 | 777 | 398 | 57.8 | 115.6 | 57.8 | (3.1) | 99.9 | 1,020 | 147.9 | 78.1 |
MYFEMBREE® | 66 | 73 | 7 | 10.1 | 10.9 | 0.8 | (0.3) | 8.4 | 85 | 12.3 | 88.6 |
GEMTESA® | 283 | 486 | 203 | 43.2 | 72.3 | 29.1 | (1.9) | 67.5 | 588 | 85.3 | 84.8 |
RETHYMIC® | 33 | 30 | (3) | 5.1 | 4.6 | (0.5) | (0.1) | (10.5) | 45 | 6.5 | 70.0 |
APTIOM® | 200 | 85 | (115) | 30.5 | 12.6 | (17.9) | (0.3) | (58.7) | 85 | 12.3 | 102.2 |
Others | 43 | 44 | 2 | 6.5 | 6.6 | 0.1 | (0.2) | 1.1 | 340 | 49.3 | 84.4 |
Export products/ One-time revenue, etc.* | 172 | 234 | 62 | 26.2 | 35.0 | 8.8 | (0.9) | 33.4 | |||
Total | 1,175 | 1,730 | 555 | 179.4 | 257.5 | 78.1 | (6.8) | 43.6 | 2,163 | 313.6 | 82.1 |
ORGOVYX® and GEMTESA® revenue increased significantly year-on-year
APTIOM® revenue decreased due to loss of exclusivity
Sales milestone revenue from ORGOVYX® has been recognized
* Major items included in Export products/One-time revenue, etc. | |||
Q3YTD FY 2024 Results | Deferred revenue from $147M the collaboration with Pfizer | Q3YTD FY 2025 Results | Deferred revenue from $66M the collaboration with Pfizer Sales milestone revenue from $100M ORGOVYX® |
Average rates:
Q3 FY2024 Results : 1US$ = ¥152.64 Q3 FY2025 Results : 1US$ = ¥148.71
FY2025 forecasts : 1US$ = ¥145.00
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 4
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |